Remove 2014 Remove Communication Remove Compounding
article thumbnail

COVID-19 and the digital pharma marketing revolution

pharmaphorum

Healthcare companies have been in the vanguard of this change, with an enormous rise in the use of telehealth and all forms of digital communications. This switch to digital technology is meaning the pharma industry is having to change the way it communicates with physicians.

article thumbnail

Top Performing Drug of 2021 - Trulicity (February Edition)

PharmaShots

In the US, Trulicity is protected by a compound patent (2027) and by biologics data protection (2026). million patients’ journeys with type 2 diabetes since 2014. Active Ingredient: dulaglutide Dosage Forms & Strengths: Injection: 0.75 mL, 3 mg/0.5 Trulicity has been a part of over 2.8

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Too Much of a Good Thing? Unpacking the Rise of Polypharmacy in Seniors

PharmD Live

According to the Journal of the American Medical Association, about 40% of older adults in the community and up to 60% of those in nursing homes are on five or more medications. Data from the U.S. shows that the proportion of older adults taking five or more medications tripled from 13.8% in 1994 to 42.4%

article thumbnail

Target Pharmacy Failure: What Happened

The Happy PharmD

billion in revenue by 2014, it paled in comparison to the colossal figures of CVS and Walgreens, which raked in $139 billion and $76 billion, respectively. Target’s overall profit margins were low, compounded by costly operational issues and the aftermath of shutting down its Canadian operations, which resulted in a $2.5

article thumbnail

Contamination Trends & Proposed Solutions

ISPE

5 , 8 Compounding pharmacies were commonly mentioned as sources of microbial cross-contamination, especially in the US. 9 , 15 This has led to compounding pharmacies completing high-volume activities such as mass repackaging, thereby increasing the risk of cross-contamination. Compounding Pharmacies: Who Is in Charge?”

article thumbnail

Three strategies for managing loss of exclusivity successfully

pharmaphorum

Eli Lilly’s Humalog compound and formulation patents expired in 2013 and 2014, respectively. Instead, maintain face-to-face communication around the time of LOE – when generic competitors enter the market it can be really valuable way to maintain already loyal customers. 3) Understand stakeholder drivers in each market.

article thumbnail

Accommodating Multiple Modalities in the Same Facility

ISPE

From a regulatory perspective, the only products that are to be excluded are sensitizing agents, including penicillins and cephalosporins (beta-lactams); potentially genotoxic compounds; and potentially OEB 5 compounds where the risk assessment indicates the compound cannot be adequately controlled. Published 2014.